Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

被引：5
|
作者：
Cao, Yi [1 ,2 ]
Li, Yunjin [1 ,2 ]
Liu, Ruijie [1 ]
Zhou, Jianhua [1 ,2 ]
Wang, Kuansong [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China
[2] Cent South Univ, Sch Basic Med Sci, Dept Pathol, Changsha 410008, Peoples R China
来源：
CANCERS | 2023年 / 15卷 / 09期
基金：
中国国家自然科学基金;
关键词：
HER2-positive breast cancer; targeted therapy; resistance; anti-resistance; TRASTUZUMAB RESISTANCE; PROMOTES RESISTANCE; MONOCLONAL-ANTIBODY; SPLICE VARIANT; PHASE-II; HER2; GROWTH; EXPRESSION; LAPATINIB; CELLS;
D O I：
10.3390/cancers15092568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15-30% of breast cancers. In HER2positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental mechanisms of drug resistance in the targeted therapies of HER2positive breast cancer and summarizes recent research progress in this field, including preclinical and basic research studies.
引用
收藏
页数：27
相关论文
共 50 条
  • [31] Dual HER2-targeted approaches in HER2-positive breast cancer
    Eugene R. Ahn
    Charles L. Vogel
    Breast Cancer Research and Treatment, 2012, 131 : 371 - 383
  • [32] TARGETED THERAPIES HER2-positive breast cancer-sifting through many good options
    Krop, Ian E.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (06) : 312 - 313
  • [33] Current and emerging therapies of HER2-positive metastatic breast cancer
    Hernandez-Blanquisett, Abraham
    Touya, Diego
    Strasser-Weippl, Kathrin
    Ruiz, Rossana
    St Louis, Jessica
    Goss, Paul
    BREAST, 2016, 29 : 170 - 177
  • [34] Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
    Schlam, Ilana
    Tarantino, Paolo
    Tolaney, Sara M.
    CANCERS, 2022, 14 (16)
  • [35] Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
    Tapia, Marta
    Hernando, Cristina
    Martinez, Maria Teresa
    Burgues, Octavio
    Tebar-Sanchez, Cristina
    Lameirinhas, Ana
    Agreda-Roca, Anna
    Torres-Ruiz, Sandra
    Garrido-Cano, Iris
    Lluch, Ana
    Bermejo, Begona
    Eroles, Pilar
    CANCERS, 2023, 15 (18)
  • [36] Advanced HER2-positive gastric cancer: Current and future targeted therapies
    Pazo Cid, Roberto A.
    Anton, Antonio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) : 350 - 362
  • [37] TARGETING THERAPEUTIC RESISTANCE IN HER2-POSITIVE BREAST CANCER
    Goel, Shom
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 82 - 82
  • [38] miRNAs in resistance to lapatinib in HER2-positive breast cancer
    Haley, V.
    Cavicchioli, F.
    Shia, A.
    O'Leary, K.
    Balakrishnan, L.
    Lo Nigro, C.
    Schmid, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S121 - S121
  • [39] The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
    Bragina, Olga D.
    Deyev, Sergei M.
    Chernov, Vladimir, I
    Tolmachev, Vladimir M.
    ACTA NATURAE, 2022, 14 (02): : 4 - 15
  • [40] Exploring Targeted Therapy for HER2-Positive Metastatic Breast Cancer
    Terrie, Yvette C.
    US PHARMACIST, 2022, 47 (10) : 34 - 39
12345